# MedTech Venture Partners

> MedTech Venture Partners is a VC fund in San Francisco backing Health Care and Medical Device. See 11 investments, check sizes, portfolio. Updated Aug 2026.

- Type: VC Fund
- Location: San Francisco, United States
- Total investments: 11
- Last investment: Jun 2026
- Lead investor: 18%
- Fund size: $3.8M
- Last fund: Jul 2019
- Last updated: Aug 2026
- Website: https://www.medtechvp.com

MedTech Venture Partners is a VC fund in San Francisco focused on Health Care and Medical Device. At MedTech Venture Partners, we fund and support medical technology entrepreneurs.Combined, our team has overseen the conception, development, and launch of over 30 medical devices and diagnostics products. We scaled early stage device businesses, operated large ones, we have extensive clinical and regulatory experience globally, and participatedin buying and selling technologies, products, and companies. We believe our experience allows us to better understand device entrepreneurs and help them succeed.Together with our partners at UCSF we are building an exciting ecosystem around early stage medical devices.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 6 | 55% |
| Medical Device | 5 | 45% |
| Medical | 4 | 36% |
| Therapeutics | 2 | 18% |
| Neuroscience | 1 | 9% |

6 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series B | 4 | 36% |
| Series A | 2 | 18% |
| Series C | 2 | 18% |
| Series D | 1 | 9% |
| Series E | 1 | 9% |

6 stages tracked in total.

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| GT Medical Technologies | GT Medical Technologies is a medical technology company focused on improving outcomes for patients with brain tumors through treatment solutions. It was established by to address unmet needs in neuro-oncology and advance the standard of care for patients with operable brain tumors. The company's flagship product, GammaTile®, is an FDA-cleared,bioabsorbable collagen implant embedded with radiation seeds that delivers targeted radiation therapy directly to the surgical cavity immediately following tumor removal. By providing localized treatment at the time of surgery, GammaTile is designed to target residual cancer cells while reducing radiation exposure to surrounding healthy brain tissue. This approach aims to help prevent tumor recurrence and improve patient outcomes. | $100M | Series E | Jun 09, 2026 |  |
| GT Medical Technologies | GT Medical Technologies, Inc. (GT), an Arizona-based medical device company, is focused on improving the lives of patients with brain tumors. GT has developed an innovative approach to treatment by combining a conformable collagen matrix with brachytherapy (radiation) seeds. The company's first product, GammaTile™ is protected by 10 US and 2Canadian issued patents, and 1 EPO patent. The product has the promise to revolutionize treatment for 176,000 patients/year in the US alone. To date, we have treated 120 patients with recurrent brain tumors in a clinical trial at Barrow Neurological Institute (BNI) and observed significant clinical improvement. | $53.3M | Series D | Jan 16, 2025 |  |
| Zenflow | Zenflow was founded in 2014 by a team of Stanford University Biodesign Fellows working in collaboration with top global urologists. After witnessing patients' frustration with existing treatment options, the founders made it their mission to find a better solution to this large unmet clinical need. | $24M | Series C | Nov 18, 2024 |  |
| Centese | Develops cardiothoracic post-operative medical equipment for post-operative surgical care and patient monitoring. | $15M | Series B | Nov 21, 2023 |  |
| GT Medical Technologies | GT Medical Technologies is a medical technology company focused on improving outcomes for patients with brain tumors through treatment solutions. It was established by to address unmet needs in neuro-oncology and advance the standard of care for patients with operable brain tumors. The company's flagship product, GammaTile®, is an FDA-cleared,bioabsorbable collagen implant embedded with radiation seeds that delivers targeted radiation therapy directly to the surgical cavity immediately following tumor removal. By providing localized treatment at the time of surgery, GammaTile is designed to target residual cancer cells while reducing radiation exposure to surrounding healthy brain tissue. This approach aims to help prevent tumor recurrence and improve patient outcomes. | $45M | Series C | Mar 23, 2023 |  |
| Akura Medical | Akura Medical offers products and services centered on mechanical thrombectomy and imaging software for venous thromboembolism treatment. Its Katana Thrombectomy System uses a steerable catheter with integrated jet-based technology to access clot material, break it down, and support clot removal during a procedure. The system provides proceduralfeedback intended to help clinicians assess clot engagement and clearance while operating the device. Akura Medical also develops NavIQ, a software tool that transforms CT angiograms into 3D vascular models that display clot location and morphology to guide procedural planning. Together, these products form a workflow that supports physicians from pre-procedure assessment through clot extraction in cases involving pulmonary embolism and related VTE conditions. | $25M | Series A | Jan 10, 2022 |  |
| Zenflow | Zenflow was founded in 2014 by a team of Stanford University Biodesign Fellows working in collaboration with top global urologists. After witnessing patients' frustration with existing treatment options, the founders made it their mission to find a better solution to this large unmet clinical need. | $24.4M | Series B | Apr 15, 2021 |  |
| GT Medical Technologies | GT Medical Technologies, Inc. (GT), an Arizona-based medical device company, is focused on improving the lives of patients with brain tumors. GT has developed an innovative approach to treatment by combining a conformable collagen matrix with brachytherapy (radiation) seeds. The company's first product, GammaTile™ is protected by 10 US and 2Canadian issued patents, and 1 EPO patent. The product has the promise to revolutionize treatment for 176,000 patients/year in the US alone. To date, we have treated 120 patients with recurrent brain tumors in a clinical trial at Barrow Neurological Institute (BNI) and observed significant clinical improvement. | $16M | Series B | Nov 23, 2020 |  |
| GT Medical Technologies | GT Medical Technologies is a medical technology company focused on improving outcomes for patients with brain tumors through treatment solutions. It was established by to address unmet needs in neuro-oncology and advance the standard of care for patients with operable brain tumors. The company's flagship product, GammaTile®, is an FDA-cleared,bioabsorbable collagen implant embedded with radiation seeds that delivers targeted radiation therapy directly to the surgical cavity immediately following tumor removal. By providing localized treatment at the time of surgery, GammaTile is designed to target residual cancer cells while reducing radiation exposure to surrounding healthy brain tissue. This approach aims to help prevent tumor recurrence and improve patient outcomes. | $16M | Series B | Nov 23, 2020 |  |
| GT Medical Technologies | GT Medical Technologies, Inc. (GT), an Arizona-based medical device company, is focused on improving the lives of patients with brain tumors. GT has developed an innovative approach to treatment by combining a conformable collagen matrix with brachytherapy (radiation) seeds. The company's first product, GammaTile™ is protected by 10 US and 2Canadian issued patents, and 1 EPO patent. The product has the promise to revolutionize treatment for 176,000 patients/year in the US alone. To date, we have treated 120 patients with recurrent brain tumors in a clinical trial at Barrow Neurological Institute (BNI) and observed significant clinical improvement. | $10M | Series A | Jan 31, 2019 |  |

10 of 11 investments shown.

## Co-investors
- [MVM Life Science Partners](https://shizune.co/investors/profile/mvm-life-science-partners) — VC Fund, 5 deals together
- [BlueStone Venture Partners](https://shizune.co/investors/profile/bluestone-venture-partners) — VC Fund, 4 deals together
- [Gilde Healthcare](https://shizune.co/investors/profile/gilde-healthcare-partners) — VC Fund, 3 deals together
- [Evidity Health Capital](https://shizune.co/investors/profile/canepa-advanced-healthcare-fund) — VC Fund, 2 deals together
- [FemHealth Ventures](https://shizune.co/investors/profile/femhealth-ventures) — VC Fund, 2 deals together
- [F-Prime](https://shizune.co/investors/profile/f-prime-capital-partners) — VC Fund, 2 deals together

## Similar investors

### Similar stage
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund
- [FJ Labs](https://shizune.co/investors/profile/fj-labs) — VC Fund

## FAQ

### What does MedTech Venture Partners invest in?

MedTech Venture Partners invests primarily in Health Care, Medical Device and Medical startups, most often at Series B and Series A stage. Most of the 11 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did MedTech Venture Partners last invest?

The most recent investment recorded for MedTech Venture Partners closed in Jun 2026. Shizune tracks 11 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co